BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Pharmaceuticals to Participate in September Investor Conferences

Supernus (SUPN)SupernusCompany update

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the

Related news

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

SUPNSupernus2026-11-02 14:18 EST

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

ABOSAcumen Pharmaceuticals2026-09-10 20:00 EST

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

CLNNClene Inc.2026-09-03 12:00 EST

Clene to Present at Upcoming September Investor Conferences

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-11-02 14:18 EST

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

SUPNSupernus2026-10-29 20:05 EST

Supernus Announces Third Quarter 2026 Financial Results

SUPNSupernus2026-10-28 12:30 EST

Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign

SUPNSupernus2026-10-21 23:45 EST

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

Stock data

Close
26.74 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States